Enhancing bone regeneration and osseointegration using rhPTH(1-34) and dimeric <sup>R25C</sup>PTH(1-34) in an osteoporotic beagle model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39625374.
- Also identified by DOI 10.7554/eLife.93830 and PMC identifier 11614385.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This study investigates the effects of two parathyroid hormone (PTH) analogs, rhPTH(1-34) and dimeric <sup>R25C</sup>PTH(1-34), on bone regeneration and osseointegration in a postmenopausal osteoporosis model using beagle dogs. Twelve osteoporotic female beagles were subjected to implant surgeries and assigned to one of three groups: control, rhPTH(1-34), or dimeric <sup>R25C</sup>PTH(1-34). Bone regeneration and osseointegration were evaluated after 10 weeks using micro-computed tomographic (micro-CT), histological analyses, and serum biochemical assays. Results showed that the rhPTH(1-34) group demonstrated superior improvements in bone mineral density, trabecular architecture, and osseointegration compared to controls, while the dimeric <sup>R25C</sup>PTH(1-34) group exhibited similar, though slightly less pronounced, anabolic effects. Histological and TRAP assays indicated both PTH analogs significantly enhanced bone regeneration, especially in artificially created bone defects. The findings suggest that both rhPTH(1-34) and dimeric <sup>R25C</sup>PTH(1-34) hold potential as therapeutic agents for promoting bone regeneration and improving osseointegration around implants in osteoporotic conditions, with implications for their use in bone-related pathologies and reconstructive surgeries.
Medical subject headings
- Osseointegration
- Bone Regeneration
- Disease Models, Animal
- Parathyroid Hormone
- Osteoporosis